SI
PCRX icon

Scout Investments’s Pacira BioSciences PCRX Stock Holding History

Scout Investments’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-125,571
Closed -$3.59M – 207
2024
Q2 		$3.59M Sell
125,571
-12,010
-9% -$342K 0.1% 190
2024
Q1 		$4.01M Sell
137,581
-8,764
-6% -$269K 0.1% 189
2023
Q4 		$4.94M Sell
146,345
-2,299
-2% -$67.3K 0.12% 189
2023
Q3 		$4.44M Sell
148,644
-4,321
-3% -$156K 0.1% 193
2023
Q2 		$5.54M Sell
152,965
-4,548
-3% -$188K 0.11% 186
2023
Q1 		$6.43M Buy
157,513
+8,985
+6% +$357K 0.13% 172
2022
Q4 		$5.73M Sell
148,528
-2,469
-2% -$120K 0.12% 179
2022
Q3 		$8.03M Buy
150,997
+6,021
+4% +$335K 0.17% 154
2022
Q2 		$8.45M Buy
144,976
+14,364
+11% +$941K 0.17% 153
2022
Q1 		$9.97M Sell
130,612
-173
-0.1% -$11.5K 0.16% 152
2021
Q4 		$7.87M Sell
130,785
-2,951
-2% -$163K 0.11% 211
2021
Q3 		$7.49M Buy
133,736
+2,514
+2% +$145K 0.11% 225
2021
Q2 		$7.96M Buy
131,222
+16,488
+14% +$1.04M 0.12% 223
2021
Q1 		$8.04M Buy
+114,734
New +$8.2M 0.12% 236

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Scout Investments's PCRX Position: Q3 2024 in Review

Scout Investments sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 125,571 shares — an estimated $3.59M sold.

Scout Investments first reported a position in PCRX in Q1 2021 and held it in 14 quarters. The position peaked at $9.97M in Q1 2022. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

  • Scout Investments reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
  • Scout Investments sold 125,571 Pacira BioSciences shares in Q3 2024, an estimated $3.59M.
  • Scout Investments first reported a position in Pacira BioSciences in Q1 2021 and held it in 14 quarters.
  • Scout Investments's Pacira BioSciences position peaked at $9.97M in Q1 2022.
  • 239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on Scout Investments's 13F filing for Q3 2024, filed 12 Nov 2024.